148 related articles for article (PubMed ID: 17599907)
1. Mechanism of activation of a G protein-coupled receptor, the human cholecystokinin-2 receptor.
Marco E; Foucaud M; Langer I; Escrieut C; Tikhonova IG; Fourmy D
J Biol Chem; 2007 Sep; 282(39):28779-28790. PubMed ID: 17599907
[TBL] [Abstract][Full Text] [Related]
2. Linking non-peptide ligand binding mode to activity at the human cholecystokinin-2 receptor.
Foucaud M; Marco E; Escrieut C; Low C; Kalindjian B; Fourmy D
J Biol Chem; 2008 Dec; 283(51):35860-8. PubMed ID: 18936102
[TBL] [Abstract][Full Text] [Related]
3. Distinct CCK-2 receptor conformations associated with β-arrestin-2 recruitment or phospholipase-C activation revealed by a biased antagonist.
Magnan R; Escrieut C; Gigoux V; De K; Clerc P; Niu F; Azema J; Masri B; Cordomi A; Baltas M; Tikhonova IG; Fourmy D
J Am Chem Soc; 2013 Feb; 135(7):2560-73. PubMed ID: 23323542
[TBL] [Abstract][Full Text] [Related]
4. Insights into the cholecystokinin 2 receptor binding site and processes of activation.
Paillasse MR; Deraeve C; de Medina P; Mhamdi L; Favre G; Poirot M; Silvente-Poirot S
Mol Pharmacol; 2006 Dec; 70(6):1935-45. PubMed ID: 16998007
[TBL] [Abstract][Full Text] [Related]
5. Characterization of a novel five-transmembrane domain cholecystokinin-2 receptor splice variant identified in human tumors.
Sanchez C; Escrieut C; Clerc P; Gigoux V; Waser B; Reubi JC; Fourmy D
Mol Cell Endocrinol; 2012 Feb; 349(2):170-9. PubMed ID: 22040601
[TBL] [Abstract][Full Text] [Related]
6. Partial agonism, neutral antagonism, and inverse agonism at the human wild-type and constitutively active cholecystokinin-2 receptors.
Foucaud M; Tikhonova IG; Langer I; Escrieut C; Dufresne M; Seva C; Maigret B; Fourmy D
Mol Pharmacol; 2006 Mar; 69(3):680-90. PubMed ID: 16293711
[TBL] [Abstract][Full Text] [Related]
7. Identification of tyrosine 189 and asparagine 358 of the cholecystokinin 2 receptor in direct interaction with the crucial C-terminal amide of cholecystokinin by molecular modeling, site-directed mutagenesis, and structure/affinity studies.
Galés C; Poirot M; Taillefer J; Maigret B; Martinez J; Moroder L; Escrieut C; Pradayrol L; Fourmy D; Silvente-Poirot S
Mol Pharmacol; 2003 May; 63(5):973-82. PubMed ID: 12695525
[TBL] [Abstract][Full Text] [Related]
8. Development of a highly selective allosteric antagonist radioligand for the type 1 cholecystokinin receptor and elucidation of its molecular basis of binding.
Dong M; Vattelana AM; Lam PC; Orry AJ; Abagyan R; Christopoulos A; Sexton PM; Haines DR; Miller LJ
Mol Pharmacol; 2015 Jan; 87(1):130-40. PubMed ID: 25319540
[TBL] [Abstract][Full Text] [Related]
9. A novel mechanism for JAK2 activation by a G protein-coupled receptor, the CCK2R: implication of this signaling pathway in pancreatic tumor models.
Ferrand A; Kowalski-Chauvel A; Bertrand C; Escrieut C; Mathieu A; Portolan G; Pradayrol L; Fourmy D; Dufresne M; Seva C
J Biol Chem; 2005 Mar; 280(11):10710-5. PubMed ID: 15640156
[TBL] [Abstract][Full Text] [Related]
10. Valine-286 residue in the third intracellular loop of the cholecystokinin 2 receptor exerts a pivotal role in cholecystokinin 2 receptor mediated intracellular signal transduction in human colon cancer cells.
Yu HG; Schäfer H; Mergler S; Müerköster S; Cramer T; Höcker M; Herzig KH; Schmidt WE; Schmitz F
Cell Signal; 2005 Dec; 17(12):1505-15. PubMed ID: 15951156
[TBL] [Abstract][Full Text] [Related]
11. Agonist-induced conformational changes in bovine rhodopsin: insight into activation of G-protein-coupled receptors.
Bhattacharya S; Hall SE; Vaidehi N
J Mol Biol; 2008 Oct; 382(2):539-55. PubMed ID: 18638482
[TBL] [Abstract][Full Text] [Related]
12. Evidence for a direct and functional interaction between the regulators of G protein signaling-2 and phosphorylated C terminus of cholecystokinin-2 receptor.
Langer I; Tikhonova IG; Boulègue C; Estève JP; Vatinel S; Ferrand A; Moroder L; Robberecht P; Fourmy D
Mol Pharmacol; 2009 Mar; 75(3):502-13. PubMed ID: 19064631
[TBL] [Abstract][Full Text] [Related]
13. Modeled structure of a G-protein-coupled receptor: the cholecystokinin-1 receptor.
Archer-Lahlou E; Tikhonova I; Escrieut C; Dufresne M; Seva C; Pradayrol L; Moroder L; Maigret B; Fourmy D
J Med Chem; 2005 Jan; 48(1):180-91. PubMed ID: 15634012
[TBL] [Abstract][Full Text] [Related]
14. Evidence that interspecies polymorphism in the human and rat cholecystokinin receptor-2 affects structure of the binding site for the endogenous agonist cholecystokinin.
Langer I; Tikhonova IG; Travers MA; Archer-Lahlou E; Escrieut C; Maigret B; Fourmy D
J Biol Chem; 2005 Jun; 280(23):22198-204. PubMed ID: 15817487
[TBL] [Abstract][Full Text] [Related]
15. Insights into the binding and activation sites of the receptors for cholecystokinin and gastrin.
Foucaud M; Archer-Lahlou E; Marco E; Tikhonova IG; Maigret B; Escrieut C; Langer I; Fourmy D
Regul Pept; 2008 Jan; 145(1-3):17-23. PubMed ID: 17961734
[TBL] [Abstract][Full Text] [Related]
16. Structure of cholecystokinin receptor binding sites and mechanism of activation/inactivation by agonists/antagonists.
Fourmy D; Escrieut C; Archer E; Galès C; Gigoux V; Maigret B; Moroder L; Silvente-Poirot S; Martinez J; Fehrentz JA; Pradayrol L
Pharmacol Toxicol; 2002 Dec; 91(6):313-20. PubMed ID: 12688374
[TBL] [Abstract][Full Text] [Related]
17. Relevance of rhodopsin studies for GPCR activation.
Deupi X
Biochim Biophys Acta; 2014 May; 1837(5):674-82. PubMed ID: 24041646
[TBL] [Abstract][Full Text] [Related]
18. Phage antibody library screening for the selection of novel high-affinity human single-chain variable fragment against gastrin receptor: an in silico and in vitro study.
Jalilzadeh-Razin S; Mantegi M; Tohidkia MR; Pazhang Y; Pourseif MM; Barar J; Omidi Y
Daru; 2019 Jun; 27(1):21-34. PubMed ID: 30607886
[TBL] [Abstract][Full Text] [Related]
19. The biologically crucial C terminus of cholecystokinin and the non-peptide agonist SR-146,131 share a common binding site in the human CCK1 receptor. Evidence for a crucial role of Met-121 in the activation process.
Escrieut C; Gigoux V; Archer E; Verrier S; Maigret B; Behrendt R; Moroder L; Bignon E; Silvente-Poirot S; Pradayrol L; Fourmy D
J Biol Chem; 2002 Mar; 277(9):7546-55. PubMed ID: 11724786
[TBL] [Abstract][Full Text] [Related]
20. SRC regulates constitutive internalization and rapid resensitization of a cholecystokinin 2 receptor splice variant.
Chao C; Ives KL; Goluszko E; Kolokoltsov AA; Davey RA; Townsend CM; Hellmich MR
J Biol Chem; 2005 Sep; 280(39):33368-73. PubMed ID: 16079138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
